November 9, 2020

AbCellera today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. 

Read AbCellera news release

VPRI News Category